Dianthus Therapeutics Stock Alpha and Beta Analysis
| DNTH Stock | 41.83 1.32 3.06% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Dianthus Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Dianthus Therapeutics over a specified time horizon. Remember, high Dianthus Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Dianthus Therapeutics' market risk premium analysis include:
Beta 0.57 | Alpha 0.18 | Risk 3.28 | Sharpe Ratio 0.0424 | Expected Return 0.14 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Dianthus Therapeutics Backtesting, Dianthus Therapeutics Valuation, Dianthus Therapeutics Correlation, Dianthus Therapeutics Hype Analysis, Dianthus Therapeutics Volatility, Dianthus Therapeutics History and analyze Dianthus Therapeutics Performance. Dianthus Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Dianthus Therapeutics market risk premium is the additional return an investor will receive from holding Dianthus Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Dianthus Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Dianthus Therapeutics' performance over market.| α | 0.18 | β | 0.57 |
Dianthus Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Dianthus Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Dianthus Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Dianthus Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Dianthus Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Dianthus Therapeutics shares will generate the highest return on investment. By understating and applying Dianthus Therapeutics stock market price indicators, traders can identify Dianthus Therapeutics position entry and exit signals to maximize returns.
Dianthus Therapeutics Return and Market Media
The median price of Dianthus Therapeutics for the period between Mon, Sep 29, 2025 and Sun, Dec 28, 2025 is 38.72 with a coefficient of variation of 10.07. The daily time series for the period is distributed with a sample standard deviation of 3.88, arithmetic mean of 38.58, and mean deviation of 3.58. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting | 10/29/2025 |
2 | Dianthus Therapeutics Assessing Valuation Following Positive Claseprubart Trial Results and Pipeline Progress | 11/11/2025 |
3 | How Investors Are Reacting To Dianthus Therapeutics Advancing Claseprubart After Positive Phase 2 Results | 11/14/2025 |
4 | Candriam S.C.A. Has 4.48 Million Holdings in Dianthus Therapeutics, Inc. DNTH - MarketBeat | 11/17/2025 |
5 | Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference | 11/24/2025 |
6 | Ensign Peak Advisors Inc Invests 2.50 Million in Dianthus Therapeutics, Inc. DNTH - MarketBeat | 11/28/2025 |
7 | Disposition of 20000 shares by Ryan Savitz of Dianthus Therapeutics at 45.18 subject to Rule 16b-3 | 12/04/2025 |
8 | Wedbush Reiterates Outperform Rating for Dianthus Therapeutics - MarketBeat | 12/22/2025 |
About Dianthus Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Dianthus or other stocks. Alpha measures the amount that position in Dianthus Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Payables Turnover | 0.09 | 0.0855 | Days Of Inventory On Hand | 1.9K | 1.7K |
Dianthus Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Dianthus Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Dianthus Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Dianthus Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Dianthus Therapeutics. Please utilize our Beneish M Score to check the likelihood of Dianthus Therapeutics' management manipulating its earnings.
| 8th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 8th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Dianthus Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Dianthus Therapeutics Backtesting, Dianthus Therapeutics Valuation, Dianthus Therapeutics Correlation, Dianthus Therapeutics Hype Analysis, Dianthus Therapeutics Volatility, Dianthus Therapeutics History and analyze Dianthus Therapeutics Performance. For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Dianthus Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.